Increasing prevalence of cancer Drives Buprenorphine Market Growth from USD 5.52 Bn in 2023
Global Bamboo Market Key Takeaways
• In terms of Application, the Opioid segment is expected to exhibit the highest share during the forecast period. This is owing to the increasing rate of opioid use disorder among people.
• By route of administration, the sublingual segment is expected to contribute the largest share, driven by extensive usage in the treatment of opioid addiction.
• Based on Distribution Channel, the retail pharmacies segment is projected to hold highest share by 2030, owing to rising rate of new retail pharmacies.
• Coherent Market Insights forecasts that North America will account for 45.1% market share by 2032. The growth is attributed to the rising prescription of Buprenorphine in the region. According to an article published by the American Medical Association, after obtaining license from the US Food and Drug Administration Buprenorphine get the chance to increase access among the drugs.
Request for a sample of this research report @https://www.coherentmarketinsights.com/insight/request-sample/4237
Increasing approval of Buprenorphine treatment and Rising incidences of cancer
A new report by Coherent Market Insights outlines significant trends in the Buprenorphine market. Increasing approval of Buprenorphine treatment will drive demand in the global market during the forecast period. Moreover, the rising prevalence of cancer is also boosting demand in the global market.
Adverse Side effect of Buprenorphine
The global Buprenorphine market growth is hampered by the adverse effects of Buprenorphine during the forecast period. For instance, as per the article published by the National Center of Biotechnology information, the use of Buprenorphine provides some anticholinergic effects that will lead to central nervous system depression. This also led to several side effects such as sweating, dry mouth, miosis, urine retention, nausea, sleepiness, and dizziness.
Opportunities for Growth
The global Buprenorphine market has significant opportunities for growth in emerging countries such as Latin America and Asia Pacific. Factors such as the growing rate of cancer and rising opioid dependency rate in these regions are expected to boost demand in the global Buprenorphine market. Leading countries such as India and Brazil where the healthcare infrastructure is developing use Buprenorphine. Buprenorphine is widely used in pain management and addiction treatment. Additionally, advancements made in the formulation of Buprenorphine like the development of long-acting injectable versions, provide avenues for expansion.
Emerging Market Trends
• Growing adoption of Buprenorphine for the treatment of opioid crisis will drive demand in the global market. Moreover, increasing approval of Buprenorphine-based treatment will boost demand as healthcare providers are now using it as a part of comprehensive addition management programs.
• The rising trend for the development and adoption of long-lasting and extended-release formulations of Buprenorphine. This formulation will help in minimizing the rate of dosing and provide a stable drug level over time.
Analyst’s View
“The global Buprenorphine market is poised for notable growth, driven by the increasing rate of people who are suffering from opioid disorder. Medical institutions and doctors are now using Buprenorphine for the treatment of opioid disorders such as opioid addiction,” said senior analyst Ghanshyam Shrivastava. “Despite these growth prospectus, the market faces challenge by adverse side effect associated with the use of Buprenorphine.”
Competitor Insights
Key companies in Buprenorphine market include:
– Mallinckrodt
– Noramco
– Unichem Laboratories Ltd.
– Sanofi
– Johnson Matthey
– Arevipharma Gmbh
– Resonance Laboratories Pvt Ltd
– Sun Pharmaceutical Industries Limited
– Rusan Pharma Ltd.
– Micro Orgo Chem
– Fran Shimi Pharmaceutical
– Indivior PLC
– Titan Pharmaceutical Inc
– Hikma Pharmaceuticals PLC
Key Development
In January 2025, ZIM Laboratories and Neuraxpharm Group stated that the Committee for Medicinal Products for Human Use will provide authorization to the Neuraxpharm, for Buprenorphine Sublingual Film in Europe.
In May 2023, the U.S. Food and Drug Administration approved Buprenorphine an extended-release injection for subcutaneous use for the treatment of moderate to severe opioid use disorder.
Transform your Strategy with Exclusive Trending Reports:
Dyspareunia Treatment Market
Bacterial Conjunctivitis Drug Market
Lung Cancer Therapeutics Market
About Us:
Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.
Contact Us:
Mr. Raj Shah Senior Client Partner – Business Development Coherent Market Insights
Phone:
US: + 12524771362
UK: +442039578553
AUS: +61-2-4786-0457
India: +91-848-285-0837
Email: [email protected]
Website: https//www.coherentmarketinsights.com
Media ContactCompany Name: Coherent Market InsightsContact Person: Mr. Raj Shah (Senior Client Partner – Business Development)Email: Send EmailCountry: United StatesWebsite: https://www.coherentmarketinsights.com/
